Japanese Encephalitis Therapeutics – Designations, Collaborations, and Developments

Japanese Encephalitis (JE) TherapeuticsJapanese encephalitis is a viral infection that spreads by mosquito bites. The study analyzed that the Japanese encephalitis therapeutics pipeline comprises approximately 12 drug candidates in different stages of development.

Shandong Hengye Biotech Co., Ltd., and VABIOTECH, have one drug candidates each in the Phase III stage of development for the treatment of the disease. The clinical studies of the vaccine, Vero cell-derived inactivated, is currently going on in China in the Phase III stage of development for the treatment of Japanese encephalitis.

Explore Report Sample at: http://bit.ly/2BB9Qiw

The companies developing drugs for the treatment of Japanese encephalitis are laying more emphasis on the drug candidates to be developed as vaccines, due to the promising results shown by these candidates the in the clinical development. Based on molecule type, around 75.0% of the therapeutic candidates are being developed as vaccines, around 13.0% are made as peptide and 12.0% are being developed as small molecule.

In September 2017, VABIOTECH in collaboration with National Institute of Hygiene and Epidemiology (NIHE), Vietnam, initiated a Phase III, randomized, multi-centered, parallel groups assignment trial to assess the immunogenicity and safety of the JECEVAX in healthy male as well as female children of age between nine to 24 months.

Pre-Purchase Inquiry at: http://bit.ly/2DJ4Ji8

Some of the key players developing drugs for the treatment of Japanese encephalitis include Shandong Hengye Biotech, Co. Ltd., Panacea Biotec Ltd., and Ennaid Therapeutics, LLC.

Advertisements

Europe Scar Treatment Market Analysis, Size, Growth and Demand, 2023

Latin America Scar Treatment MarketThe Europe scar treatment market size was valued at $5.2 billion in 2016, which is expected to reach $9.8 billion by 2023, growing at a CAGR of 9.6% during the forecast period (2017-2023). Topical scar treatment is expected to witness highest growth during the forecast period in the European scar treatment market due to increasing disposable income, rising prevalence of chronic wounds and availability of different types of topical scar treatment products. Topical scar treatment is followed by surface scar treatment, laser scar treatment, injectable scar treatment, invasive surgical scar treatment. Among the different types of scar, post-surgical scar was the most widely treated type of scar in Europe in 2016, followed by acne scar, keloid scar & hypertrophic scar, contracture scar, and stretch mark. The contribution of hospital in the European scar treatment market was the highest in 2016 mainly due to continuously developing reimbursement structure in the region.

Explore Report Sample at: http://bit.ly/2CKCq2v

The key players in the European scar treatment market are coming up with scar treatment products with innovative technologies, especially with laser therapy approaches. For instance, in September 2015, Lumenis Ltd. Announced promising clinical data of its advanced laser platform, UltraPulse with SCAAR FX, at the 16th European Burns Association Congress, in Hannover, Germany. Laser scar therapy, especially fractional ablative laser resurfacing, has turned out to be a momentous advancement in scar treatment and management and has been increasingly adopted as a promising approach in the treatment of burns and scars.

Pre-Purchase Inquiry at: http://bit.ly/2AJ9Ywa

Some of the key players operating in the European scar treatment market include Merz GmbH & Company KGAA, Mölnlycke Health Care AB, Smith & Nephew Plc, Syneron Medical Ltd., Lumenis Ltd., L’oreal S.A, H&R Healthcare Ltd., Avita Medical, Arbonne International, and Laverana GmbH & Co.KG.

Asia-Pacific Sleeping Aids Market 2022 – Industry Size, Share and Growth Strategies

Asia-Pacific Sleeping Aids MarketThe Asia-Pacific sleeping aids market size was $9.3 billion in 2015 and is forecasted to grow at a CAGR of 6.6% during the period 2016-2022. Various type of sleeping disorders such as sleep apnea, insomnia, restless legs syndrome, narcolepsy and sleep walking require some or the other type of sleeping aids intervention. Sleeping aids for sleep apnea held the largest share in the Asia-Pacific market in 2015, since an increasing number of people in the region suffer from breathing problems while sleeping.

Explore Report Sample at: http://bit.ly/2memu28

The demand for sleeping aids has been rising in the region due to high consumption of sleeping pills owing to changing lifestyle, growing awareness about sleep disorders and other related problems, long working hours, and growing aging population. Some of the sleeping aids products available in the market include mattress & pillow, sleep laboratories, medication, sleep apnea devices and others. Amongst these, mattress & pillows held the highest share in the regional market, standing at 41% in 2015, since they have a direct impact on the sleeping condition of a person.

Long working hours often lead to sleep issues and the government agencies and other firms are taking action against it to improve the conditions of workers in the region. For instance, Sumitomo Mitsui Trust Bank extended its nine-hour minimum to all employees, including contract staff, in December 2016. The Japanese government has set aside about ¥400 million for the year 2017 for an incentive program to encourage small and medium-sized companies to adopt minimum rest periods to ensure better productivity. All such initiatives by the governments in various countries in the region, eventually leads to the high demand of products in the sleeping aids market in the region.

Pre-Purchase Inquiry at: http://bit.ly/2FhmNRW

Some of the other key players operating in the Asia-Pacific sleeping aids industry include Sanofi S.A., Koninklijke Philips N.V., GlaxoSmithKline PLC, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Compumedics Limited, Becton, Dickinson and Company, Eisai Co., Ltd. and Drive Medical Ltd.

Testicular Cancer Therapeutics Market – Epidemiology Analysis, Therapy and Growth, 2023

Testicular Cancer Therapeutics MarketGlobal testicular cancer therapeutics market is growing with the increasing prevalence of testicular cancer. The market is expected to witness moderate growth, since there are already more than 15 drugs that exist in the market for the treatment of testicular cancer. Increasing prevalence of cancer and rising demand for the medications with better efficacy and less side effects can be attributed as an opportunity for oncology. The regulatory bodies such as USFDA, EMA are supporting the growth of the global market by providing increased funding, designations and grants for speeding up the drug development process.

Get Free Report Sample at @ http://bit.ly/2Fd2pRN

in men that produce testosterone hormone and sperms. The cause of testicular cancer is attributable to enormous growth of testicular cells due to some abnormalities, resulting in the formation of tumor in testicles, causing testicular cancer. Cryptorchidism, inguinal hernia, congenital abnormalities, abnormal testicular development and family history can increase the risk of testicular cancer. Mumps orchitis are also one of risk factors which is a very rare complication of mumps, which involves the inflammation of testicles. Pain, swelling, discomfort, sensation of heaviness and sudden fluid accumulation in scrotum are the main symptoms of testicular cancer.

Diagnosis of testicular cancer is done through a blood test, ultrasound and biopsy. Also, the type of testicular cancer is determined with the diagnosis along with its stage. There are two types of testicular cancer- seminoma testicular cancer and non- seminoma testicular cancer. After the diagnosis, the treatment options are selected according to the stage and the type of testicular cancer. The treatment options that are available to the patients are chemotherapy, radiation therapy and surgery. Surgery include orchidectomy, removal of both the testicles, lymph node surgery and hormone replacement therapy.

Pre-Purchase Inquiry at @ http://bit.ly/2D8gzTN

Some of the key players operating in the global testicular cancer therapeutics market are Ovation Pharmaceuticals, Inc., ZIOPHARM Oncology Inc., Bristol-Myers Squibb Company, Hospira Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG and Teva Parenteral Medicines, Inc.

Acute Myeloid Leukemia Therapeutics Market – Epidemiology Analysis, Growth, 2023

Acute Myeloid Leukemia Therapeutics MarketThe global acute myeloid leukemia therapeutics market is expected to witness notable growth, in the coming year due to increase in the new innovative and targeted drug delivery system. Various factors such as rising awareness regarding cancer treatments, increasing demand for safe and successful medications, rising incidence of cancer and technological advancements have been driving the growth of the global acute myeloid leukemia therapeutics market. Apart from this, various regulatory bodies are supporting the growth of the global market with funding, designations and grants, thereby accelerating the drug development process.

Explore Report Sample at @ http://bit.ly/2CYkNgk

According to National Cancer Institute, a part of the U.S. National Institutes of Health, acute myeloid leukemia is a type of cancer that affects the blood and bone marrow. Acute myeloid leukemia is characterized by overproduction of immature white blood cells, myeloblasts or leukemic blasts. These cells crowd the bone marrow, preventing it from making normal blood cells. They can also spill out into the blood stream and circulate around the body. Due to their immaturity, these cells are unable to prevent or fight infections.

The pipeline of acute myeloid leukemia contains Durvalumab, a Phase II drug candidate of MedImmune. It is a fully human monoclonal antibody, which helps to overcome the immunosuppressive effects of B7-H1 on T-cells. Takeda Pharmaceutical Company Limited is developing a Phase II drug candidate, Alisertib, for the treatment of acute myeloid leukemia. It is an orally active, small-molecule inhibitor of the aurora A kinase. The aurora family of protein kinases is involved in the regulation of cell growth and proliferation, particularly in chromosome segregation and cytokinesis.

Pre-Purchase Inquiry at @ http://bit.ly/2qsfK5f

Many pharmaceutical companies are partnering with each other for research and development of acute myeloid leukemia. In December 2015, Massachusetts General Hospital, entered into a collaboration with Takeda to initiate a phase II trial to evaluate the efficacy of alisertib in combination with 7+3 induction chemotherapy, involving cytarabine and concurrent idarubicin or daunorubicin in patients with newly diagnosed high-risk acute myeloid leukemia. The open-label trial enrolled 39 patients in the U.S.

Some of the key players operating in the acute myeloid leukemia therapeutics market include Celgene Corporation, Eisai Co. Ltd., Bristol-Myers Squibb, Novartis AG, F. Hoffman La Roche AG, Genmab A/S, GlaxoSmithKline plc, and Takeda Pharmaceutical Company Limited.

Chronic Lymphocytic Leukemia Therapeutics Market – Epidemiology Analysis, Therapy and Demand, 2023

Chronic Lymphocytic Leukemia (CLL) Therapeutics MarketThe global chronic lymphocytic leukemia therapeutics market is expected to create more opportunities in oncology due to promising pipeline and positive clinical data of drug candidates. The existing drugs for the treatment of chronic lymphocytic leukemia is the be most effective treatment. The American Cancer Society, and other regulatory bodies are supporting the chronic lymphocytic leukemia therapeutics market by providing funding and grants. The market is being driven by different factors such as rising awareness for the cancer treatments, high demand for safe and effective medications, technologies advancements, and increasing prevalence of cancer.

Explore Report Sample at: http://bit.ly/2CF9494

Chronic lymphocytic leukemia is a type of gradually developing leukemia that affects the development of B lymphocytes (also known as B cells). On the other hand, B cells are specialized white blood cells, which produce immunoglobulins (also called antibodies) under normal conditions, and help to protect the human body against infections and diseases. In patients with chronic lymphocytic leukemia, lymphocytes undergo a malignant change and become leukemic cells.

Ono Pharmaceutical and Bristol-Myers Squibb are in the process of developing Opdivo for the treatment of chronic lymphocytic leukemia. Genentech is developing Atezolizumab, also known as MPDL 3280A, for chronic lymphocytic leukemia therapeutics, which is in Phase II stage. Atezolizumab is a monoclonal antibody targeting programmed cell death-1 ligand 1 (PD-L1). PD-L1 plays an important role in suppressing the immune system triggered by the cancer. PD-L1 acts by reducing the proliferation of antigen-specific CD8+ T-cells and controlling the accumulation of foreign antigen-specific T-cells.

Pre-Purchase Inquiry at: http://bit.ly/2Easi3h

Certain chemotherapy medications, such as Doxorubicin, Bleomycin, Vinblastine, Dacarbazine, Chlorambucil, Procarbazine Prednisolone, Mustine, Vincristine, Etoposide, Cyclophosphamide, Gemcitabine, Cisplatin and Cytarabine have been well established as a conventional method to treat Chronic lymphocytic leukemia. However, immunotherapy, combination therapy, steroids, and monoclonal antibodies are showing promising results for the treatment of chronic lymphocytic leukemia.

Some of the key players operating in the chronic lymphocytic leukemia therapeutics market are GlaxoSmithKline plc, F. Hoffmann-La Roche AG, Celgene Corporation, Biogen Inc., AbbVie, Inc., Teva Pharmaceuticals Limited, Gilead Sciences, Inc., Novartis AG, and Johnson & Johnson.